Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05349513
Recruiting Not applicable

Interest of the Tool: Evaluation of Specific Care in an Ecological Environment for Patients Suffering From Schizophrenia-like Disorders

NCT05349513 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Henri Laborit
Phase
Not applicable
Started
2022-02-23
Last updated
2026-01-13

Condition(s) studied

Patients With Schizophrenia-like Disorders

Investigational drug(s) / intervention(s)

ESSME questionnaire

ESSME questionnaire: The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.

Study summary

The study use a new ecological questionnaire called ESSME developed by a care team in order to evaluate ecological environment of patients with schizophrenia-like disorders.

Indeed, evaluation in an ecological environment would make it possible to be as close as possible to the concerns of theses patients, which could improve the care of this population, by making it possible to set with the patient objectives anchored in their daily life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * man or woman aged 18 to 65 inclusive; * diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders version number 5 (DSM-V) criteria; * patient receiving care in a Center for Rehabilitation and Intersectoral Therapeutic Activities (CREATIV); * person who consented to the study; * affiliate or beneficiary of a social security scheme. Exclusion Criteria: * patient aged under 18 or over 65; * pregnant or breastfeeding women; * person unable or unwilling to receive a home visit; * person not consenting to the study; * presence of a diagnosis of an associated neurodevelopmental disorder; * presence of a diagnosis of dementia or associated neurodegenerative process; * person with a level of French language insufficient to understand the items.

Primary outcome measure(s)

  • Correlation coefficient between the total ecological questionnaire (ESSME) score and the total score of the social autonomy scale. — 6 months
    The main judgment criterion is the correlation coefficient between the change in the total ESSME score and the change in the total score of the selected autonomy scale, the EAS over a period of 6 months. The judgment criterion will be obtained by calculating a percentage variation between the initial total score and that obtained at 6 months for each of the scales: EAS and for the ESSME tool.

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Henri Laborit Poitiers France Recruiting

More Centre Hospitalier Henri Laborit trials in France

French Observatory of ElectroConvulsive Therapy (ECT) Recruiting
tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder Recruiting
Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition Recruiting
tDCS and Symptom Provocation in Treatment-Resistant OCD Starting soon
Influence of Control Deprivation on the Use of the Analytical Cognitive Style in Anorexic Subjects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05349513 on ClinicalTrials.gov ↗ ← All trials in France